Novartis gets access to UPenn's immunotherapies and technology
Novartis AG has teamed up with the University of Pennsylvania to develop cellular immunotherapies for cancer. The Big Pharma gets exclusive rights to UPenn’s chimeric antigen receptor technologies as well as the drug candidates that result from its use, including CART19 which targets the CD19 protein. It was discovered by the university's Carl June, MD, and is expected to start Phase II in Q4 2012.
- Gene Therapy, Cell Therapy
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.